Pharmacogenetics (PGx)
A 10-gene panel covering drug metabolism across 34 medications in cardiometabolic, GI, psychiatric, and other therapeutic areas. Identifies poor, intermediate, normal, and ultra-rapid metabolizers.
Clinical Area · Pharmacogenomics
Right drug, right dose — informed by genomics
Pharmacogenomic testing identifies how a patient's genetic profile affects their response to medications — enabling more precise prescribing, reducing trial-and-error, and minimizing adverse drug reactions. Preventive genomic panels extend this to disease risk before symptoms develop.
Preventive genomic risk
Genome-wide polygenic risk scores across 40+ disease categories including cardiovascular disease, metabolic conditions, and cancer — stratified separately for male and female patients.
Multi-cancer early detection
Cell-free DNA analysis covering five or six cancer types from a single blood draw. Appropriate for high-risk populations under physician guidance, not as a population screening tool.
Clinical indications
When to consider PGx or preventive genomics
Drug non-response or adverse reaction — identifying a pharmacogenetic basis
Polypharmacy — assessing drug-gene interactions across a medication regimen
Starting a new drug in a class with known PGx variation (antidepressants, anticoagulants, analgesics)
Preventive health — polygenic disease risk across cardiovascular, metabolic, and cancer categories
Multi-cancer early detection — cfDNA screening in appropriate risk-group populations
Cardiology — hereditary arrhythmia risk screening in individuals with family history of sudden death
Available tests
Pharmacogenomics & preventive panels through AC
GC Genome
ai-CANCERCH®
Multi-cancer early detection from cfDNA; includes five cancer types for males and six cancer types for females, including ovarian cancer.
Method: NGS
Specimen: Streck cfDNA tube
TAT: 14–21 days
GC Genome
Genome Health (Female)
Polygenic risk assessment across 45 disease categories for females, including 14 cancer types.
Method: NGS
Specimen: EDTA whole blood
TAT: 12–14 days
GC Genome
Genome Health (Male)
Polygenic risk assessment across 44 disease categories for males, including neurological, cardiovascular, metabolic, and cancer risks.
Method: NGS
Specimen: EDTA whole blood
TAT: 12–14 days
GC Genome
Genome Screen — Cancer
Genomic screening focused on inherited cancer predisposition and risk stratification.
Specimen: EDTA whole blood
GC Genome
Genome Screen — Cardiac Arrest
A 40-gene screen covering 15 disease types, including hereditary arrhythmia syndromes.
Method: NGS
Specimen: EDTA whole blood
TAT: 17–21 days
GC Genome
Pharmacogenetics (34 drugs)
Ten-gene pharmacogenetic panel predicting response across 34 drugs used in cardiometabolic, gastrointestinal, inflammatory, and other conditions.
Method: Real-time PCR
Specimen: EDTA whole blood
TAT: 10–12 days
GC Genome
Telorisk®
Telomere-related risk assessment from peripheral blood.
Specimen: EDTA whole blood
Pharmacogenomics
Discuss a PGx or preventive genomics case
Share the clinical scenario, current medications, or preventive health question. AC can help identify the most appropriate panel and interpretation pathway.
Suite 403, 133 Madina Munawara St, Amman, Jordan
+962 791 707 606 info@advancedconsensus.comMessage us on WhatsAppFor website inquiries, avoid patient names, national IDs, medical record numbers, or reports. Secure document exchange should happen through approved clinical channels.